Lifeward Shareholders Approve Transformative Oramed Partnership, Securing Up to $47M Capital Infusion
LFWD sits 68% above its 52-week low of $4.14 on light trading volume (0.3× avg).
Summary
Lifeward shareholders have approved the strategic partnership with Oramed Pharmaceuticals, enabling the transaction to proceed towards closing. This partnership is highly significant, integrating Oramed's POD™ oral delivery technology into Lifeward and expanding its operations into the biotechnology sector. Crucially, the agreement provides Lifeward with access to up to $47 million in capital, a substantial amount relative to its current market valuation, and positions Oramed to fund the POD™ platform's clinical development. This move is expected to diversify Lifeward's business, strengthen its path to profitability, and offer substantial long-term growth opportunities. Investors will now watch for the official closing of the transaction and subsequent updates on the integration and clinical progress of the new biotech platform.
At the time of this announcement, LFWD was trading at $6.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1M. The 52-week trading range was $4.14 to $35.40. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.